NCT04441931View on ClinicalTrials.gov

A Study of LY3832479 (LY-CoV016) in Healthy Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

26

Participants

Timeline

Start Date

June 19, 2020

Primary Completion Date

October 2, 2020

Study Completion Date

October 2, 2020

Conditions
Healthy
Interventions
DRUG

LY3832479

Administered IV.

DRUG

Placebo

Administered IV.

Trial Locations (1)

32117

Covance Clinical Research Inc, Daytona Beach

All Listed Sponsors
lead

Eli Lilly and Company

INDUSTRY

NCT04441931 - A Study of LY3832479 (LY-CoV016) in Healthy Participants | Biotech Hunter | Biotech Hunter